Continuous ambulatory peritoneal dialysis and the human immunodeficiency virus

Abstract

This review looks at the clinical performance of Immunodeficiency Virus (HIV) infected individuals with end stage renal disease (ESRD) treated using continuous ambulatory peritoneal dialysis (CAPD). It also considers the potential infectious nature of the peritoneal dialysis effluent (PDE) and offers suggestions on how to circumvent this risk